This is a medicine used to help control blood sugar levels in people with diabetes. It's similar to a hormone your body makes. It works by helping your body use insulin better and reducing how much sugar your liver makes.
Every report comes from a Lived member, sent anonymously.
Have you tried Saxenda / Victoza (Liraglutide) for Overweight?
Liraglutide is a once-daily prescription injection sold under two brand names with different jobs. Victoza treats type 2 diabetes: used with diet and exercise, it lowers blood sugar in adults and in children 10 years and older. In adults with type 2 diabetes who already have heart or blood vessel disease, it also lowers the risk of heart attack, stroke and death from cardiovascular causes. Saxenda is a higher-dose version approved for long-term weight management, used together with a reduced-calorie diet and more physical activity. It is approved for adults with obesity, adults who are overweight and have at least one weight-related health condition, and adolescents 12 and older with obesity who weigh more than 60 kg (about 132 pounds). Generic liraglutide is now available in the US for both uses, and liraglutide is also one of the two ingredients in Xultophy, a combination with a long-acting insulin. Because the diabetes and weight products use different doses, one should not be swapped for the other, and liraglutide should not be combined with another liraglutide product. Saxenda is also not meant to be used alongside any other medicine from the same family, known as glucagon-like peptide-1 (GLP-1) receptor agonists.
Liraglutide is a lab-made version of GLP-1, a hormone the gut releases after eating. The body breaks down its own GLP-1 within a couple of minutes. Liraglutide has been modified to resist that breakdown and lasts about 13 hours, which is why a single daily injection is enough. When blood sugar is high, liraglutide prompts the pancreas to release insulin and lowers glucagon, a hormone that tells the liver to release stored sugar. The insulin effect fades as blood sugar comes back toward normal, which is why low blood sugar is mainly a concern when liraglutide is combined with other diabetes medicines. Liraglutide also slows how quickly the stomach empties and acts on areas of the brain that regulate appetite, so many people feel full sooner and eat less. Together these effects explain the lower blood sugar seen with Victoza and the weight loss seen with Saxenda, although researchers have not pinned down exactly which brain pathways produce the appetite effect.
Liraglutide comes in prefilled multi-dose pens and is injected under the skin of the abdomen, thigh or upper arm once a day, at any time of day, with or without meals. Everyone starts at 0.6 mg a day for a week and then steps up, because a gradual climb makes nausea and other stomach side effects easier to tolerate. The starting dose is only for getting used to the medicine; it does not do much on its own. The target depends on the product. For diabetes (Victoza or its generic), the usual dose is 1.2 mg a day, raised to a maximum of 1.8 mg if blood sugar needs more control. For weight management (Saxenda or its generic), the dose rises each week over about four weeks to 3 mg a day, which is the maintenance dose for adults. Adolescents may build up more slowly and may stay at 2.4 mg if 3 mg is not tolerated. If a dose is missed, skip it and take the next one at the usual time rather than doubling up. If more than three days have passed, the label advises restarting at 0.6 mg and building up again, because jumping back in at a full dose often brings the nausea back. Rotate injection spots within the same area, use the pen only if the liquid is clear and colorless, and never share a pen with anyone, even with a new needle, because it can spread blood-borne infections. People who also use insulin give it as a separate injection and never mix the two.
Stomach and bowel effects are the most common: nausea, diarrhea, constipation, vomiting, indigestion and reduced appetite. They tend to appear when starting or after a dose increase and often ease over the following weeks. Headache, tiredness, dizziness and redness at the injection site can also occur. Saxenda raises resting heart rate by a few beats per minute on average; a racing or pounding heartbeat while at rest is worth reporting. In the Saxenda trials, about 1 in 10 adults stopped because of side effects, mostly during the first few months. Severe stomach side effects were uncommon but more frequent than with placebo. Vomiting or diarrhea that keeps you from staying hydrated, or noticeably less urine, should prompt a call to the care team right away, because dehydration has led to kidney injury in some people taking liraglutide. A few less common problems need prompt attention. Ongoing, severe pain in the upper or middle abdomen that may spread to the back, with or without vomiting, can signal pancreatitis (inflammation of the pancreas): stop liraglutide and contact a clinician right away. Upper stomach pain with fever, yellowing of the skin or eyes, or clay-colored stools can signal gallstones or an inflamed gallbladder, which occurred more often with liraglutide than with placebo; call the care team promptly. Swelling of the face, lips, tongue or throat, trouble breathing or swallowing, or fainting may be a severe allergic reaction and needs emergency care by calling 911.
Liraglutide carries a boxed warning, the most prominent warning the US Food and Drug Administration (FDA) puts on a label, about thyroid tumors. It caused tumors of the thyroid C-cells (the cells that give rise to medullary thyroid cancer) in rats and mice, and it is not known whether it does the same in people. For that reason it should not be used by anyone with a personal or family history of medullary thyroid cancer or with MEN 2 (multiple endocrine neoplasia type 2), an inherited condition that causes this cancer. A lump or swelling in the neck, trouble swallowing, shortness of breath or hoarseness that does not go away should be checked by a clinician. Low blood sugar is the main interaction to plan for. Taking liraglutide with insulin or a sulfonylurea (an older class of diabetes pills, such as glipizide) raises the risk, sometimes to a severe level, so the prescriber may lower the dose of those medicines when liraglutide starts. Children and teenagers had more low blood sugar even without those medicines. Signs include shakiness, sweating, dizziness, hunger, irritability or confusion. Eating or drinking something with fast-acting sugar, such as juice or glucose tablets, usually brings it back up, and the care team should hear about it; someone who passes out or is too confused to eat or drink safely needs emergency help. Because liraglutide slows stomach emptying, it can change how some oral medicines are absorbed, so the prescriber and pharmacist should know everything you take. Tell the surgical or anesthesia team that you take liraglutide before any procedure that involves general anesthesia or deep sedation. Food can stay in a slowed stomach even after the usual fasting, and rare cases of inhaling stomach contents during anesthesia have been reported with this class of medicines. Liraglutide is not recommended for people with severe gastroparesis (a stomach that empties very slowly). Animal studies suggest possible harm to a developing baby. Saxenda should be stopped once a pregnancy is recognized, since weight loss offers no benefit during pregnancy. For Victoza, anyone pregnant or planning pregnancy should discuss with their care team whether the benefit outweighs the risk. Anyone who has had a serious allergic reaction to liraglutide should not use it again.
Appetite and fullness often change within the first weeks, while the stomach side effects tend to be most noticeable during the dose increases. For diabetes, the effect on blood sugar is tracked with home readings and the A1c test, a blood test that reflects average blood sugar over the past two to three months. In a large trial of adults with type 2 diabetes and existing heart disease, Victoza lowered the combined rate of heart attack, stroke and cardiovascular death compared with placebo. Weight loss with Saxenda builds over months and varies widely. In a year-long trial of adults with obesity or overweight, people on Saxenda lost an average of about 7% of their body weight, compared with about 3% for those on placebo, with both groups also following diet and activity advice. About 6 in 10 people on Saxenda lost at least 5% of their weight, and about 1 in 3 lost more than 10%. Because response is so variable, the label sets a checkpoint: adults who have not lost at least 4% of their starting weight after 16 weeks are unlikely to benefit meaningfully and should stop. For adolescents the check is a drop of at least 1% in body mass index (BMI), a measure of weight relative to height, after 12 weeks on the maintenance dose. Both uses are intended as long-term treatment. Follow-up visits review benefit, side effects, heart rate and, for people with diabetes, whether other diabetes medicines need adjusting.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Saxenda / Victoza (Liraglutide), what you've noticed, or ask the community a question.